Haematology Oncology Emergency Medicine Strong — validated in >1000 patients; endorsed by ASCO and NICE guidelines
MASCC Risk Index for Febrile Neutropenia
Multinational Association for Supportive Care in Cancer (MASCC) score identifies low-risk febrile neutropenia patients suitable for oral antibiotics and potential outpatient management.
References
- Klastersky J, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038–3051.
- NICE NG144. Neutropenic sepsis: prevention and management in people with cancer. 2012 (updated 2021).
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Meropenem (Paediatric) · Carbapenem — Severe / MDR Gram-Negative Infections / Febrile Neutropenia
- Folinic Acid (Calcium Folinate / Leucovorin) · Antidote / Chemotherapy Support
- Zoledronic Acid · Bisphosphonate (IV)
- Denosumab · RANK Ligand Inhibitor (Anti-resorptive)
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Methotrexate · Chemotherapy / Immunosuppressant — Head and Neck / Granulomatosis
Pathways
Same specialty
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.